Diabetes medications present an ideal paradigm to test new safety signal detection approaches because they are used frequently in large numbers of patients with type 2 diabetes, and new products have been recently launched while suitable drug comparators remain marketed.
Given the scarcity of financial resources to fund future trials of exercise interventions, one option would be to require such evidence from pharmaceutical companies that are under increasing pressure to perform active-comparator trials for market entry.
Difference-in-differences analysis comparing ORS use (with or without zinc) in the intervention and comparator districts, before and after market-shaping activities, found that ORS use increased significantly across intervention districts from 59.8% to 76.4%, while usage across comparators decreased non-significantly from 66.4%to58.2%2%.
Comparator: The groups compared were subjects tested by WGS, WES, and CMA.
Superiority over placebo and non-inferiority to active comparators may allow drugs onto the market that are in fact less active (or safe, tolerable, convenient, etc).
Furthermore, OLA was the best comparator based on proven efficacy and market-share [ 13].
To aid in the selection of doses for further development, a marketed open-label active comparator was included in this study (TIO).
Although RCTs using placebo as a comparator fulfil the design criteria for marketing authorization (EMA and FDA), the use of a drug in clinical practice would require evidence in line with the Comparative Effectiveness Research CERR) paradigm [ 111].
No trial has used venlafaxine, the other marketed SNRI, as an active comparator.
Finally, although the phase III clinical trials used warfarin as the comparator, warfarin is not used (or even marketed) in many countries in Europe now.
